Free Trial

Kyverna Therapeutics (KYTX) Stock Forecast & Price Target

+0.57 (+4.59%)
(As of 05/24/2024 ET)

Kyverna Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 5 Analyst Ratings

Consensus Price Target

228.85% Upside
High Forecast$48.00
Average Forecast$42.75
Low Forecast$39.00
TypeCurrent Forecast
5/27/23 to 5/26/24
1 Month Ago
4/27/23 to 4/26/24
3 Months Ago
2/26/23 to 2/26/24
1 Year Ago
5/27/22 to 5/27/23
Consensus Rating
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$42.75$42.75N/AN/A
Forecasted Upside228.85% Upside54.05% UpsideN/AN/A
Get Kyverna Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.

KYTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KYTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Kyverna Therapeutics Stock vs. The Competition

TypeKyverna TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingBuyModerate BuyHold
Predicted Upside228.85% Upside834.27% Upside9.92% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/4/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/4/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$44.00+58.56%
3/4/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$48.00+72.97%
3/4/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$40.00+44.14%
3/4/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$39.00+40.54%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:04 AM ET.

KYTX Frequently Asked Questions

What is Kyverna Therapeutics's stock forecast and purchase recommendation?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Kyverna Therapeutics is $42.75, with a high forecast of $48.00 and a low forecast of $39.00. The consensus rating for Kyverna Therapeutics stock is Buy based on the current 5 buy ratings for KYTX. Learn more on KYTX's analyst rating history.

Do Wall Street analysts like Kyverna Therapeutics more than its competitors?

Analysts like Kyverna Therapeutics more than other "medical" companies. The consensus rating for Kyverna Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how KYTX compares to other companies.

Does Kyverna Therapeutics's stock price have much upside?

According to analysts, Kyverna Therapeutics's stock has a predicted upside of 54.05% based on their 12-month stock forecasts.

What analysts cover Kyverna Therapeutics?

Kyverna Therapeutics has been rated by research analysts at JPMorgan Chase & Co., Leerink Partnrs, Morgan Stanley, SVB Leerink, and Wells Fargo & Company in the past 90 days.

Stock Forecasts and Research Tools

This page (NASDAQ:KYTX) was last updated on 5/26/2024 by Staff

From Our Partners